医薬品（最終製剤）受託製造業界 - 構造、規模、市場シェア、今後の見通し、2023年版

当レポートでは、世界の医薬品（最終製剤）受託製造業界について調査し、市場の構造と規模、市場シェア、今後の見通しなどを提供しています。

目次

• エグゼクティブサマリー
• 参入企業
• 動向
• 業界の規模と構造
• 最終製剤受託製造機関の定義
• 業界の人口動態
• 世界的影響範囲と地域的影響範囲
• 剤形
• 業界構造に影響を与える大きな動き
• 製剤製造施設の買収
• 製剤製造会社の買収
• PEの買収
• 業界の規模と成長
• 最終製剤の製造
• インフレ
• 成長の要素
• 剤形別収益
• 受託製造機関（CMO）市場シェア
• 最大手CMOの特徴
• COVID-19製品の売上予測
• 最近の医薬品（最終製剤）受託製造業界の実績分析
• COVID-19の影響
• 高いインフレ効果
• サービス固有の成長
• 細胞および遺伝子治療への投資
• スポンサーとCMOの関係
• その意味
• バリューチェーン
• 企業

付録

• 調査手法
• 市場規模と成長予測の調査手法
• CMOの分類
• 参考文献
• 1次調査-主要なオピニオンリーダー
• 参考文献
• 著者について
• お問合せ

List of Tables

List of Tables

• Table 1: Dose CMO trends, 2022
• Table 2: Summary of CMO facility acquisition of dose facilities activity, 2013-22
• Table 3: CMO acquisitions of dose manufacturing facilities, 2022
• Table 4: Dedicated CMO acquisitions of companies with commercial dose capabilities, 2022
• Table 5: PE investments in the dose CMO industry, 2013-22
• Table 6: Dose revenue composition and strategic orientation of leading CMOs, 2022
• Table 7: Geographical reach of dose CMO universe, 2022
• Table 8: Further reading

List of Figures

List of Figures

• Figure 1: Leading dose CMOs, 2022
• Figure 2: Top contract dose trends in the CMO industry, 2022
• Figure 3: Geographic reach of the dose CMO universe, 2022
• Figure 4: Geographic distribution of commercial dose facilities, 2022
• Figure 5: Geographic distribution of commercial dose injectable facilities, 2022
• Figure 6: CMO count by dose revenue tiers, 2022
• Figure 7: Dose CMO revenue, 2011-22
• Figure 8: Components of growth for dose CMOs, 2021-22
• Figure 9: Dose CMO dosage form revenue segments in 2022 ($B)
• Figure 10: Dose CMO dosage form revenue segments percentage change from 2021-22 (%)
• Figure 11: Dose CMO industry market share by company revenue tier, 2022
• Figure 12: Dose CMO industry market share by company revenue tier, percentage change from 2021-22 (%)
• Figure 13: COVID-19 vaccines sales forecasts, 2022-26
• Figure 14: COVID-19 therapy sales forecasts, 2022-26
• Figure 15: COVID-19 vaccine and therapy contract manufacturing agreements
• Figure 16: CMO services sector performance, 2022
• Figure 17: Revenue growth for public CMOs
• Figure 18: Small, micro, and nano cap sponsors' dose outsourcing propensity for NMEs, 2013-22
• Figure 19: Breakdown in composition of dose-outsourced NMEs, by sponsor market cap, 2013-22
• Figure 20: The contract manufacturing value chain

Abstract

This expert trend report is a comprehensive look at the pharmaceutical finished dose contract manufacturing landscape in 2023, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.

This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2023, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.

Scope

This 63-page report gives an important expert quantitative analysis on the pharmaceutical commercial contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry (GlobalData's Contract Service Providers Database). This analysis is driven by a proprietary model of the dose manufacturing industry, which is continuously updated and refined. The 8 tables and 20 figures throughout the report illustrate major points and trends. This report is required reading for -

• CMO executives and strategic decision-makers: to improve understanding of the dose CMO industry and provide a critical input for strategic planning efforts.
• Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
• Private equity investors: they can gain a deeper understanding of the dose CMO market and important insights for identifying potential investment targets.

Reasons to Buy

This report will enable the user to answer the following questions -

• What is the geographic reach of commercial dose CMOs?
• What are revenues did the commercial contract dose manufacturing industry generate in the last year?
• What are the components of revenue change for contract dose manufacturers?
• What is the breakdown of 2022 revenues by different dosage forms?
• What are the characteristics of the largest dose CMOs?
• How did the revenue growth of Contract Dose manufacturers in 2022 compare to Contract API manufacturers?
• What is the outlook for the dose CMO industry?
• What is the outlook for COVID-19 products?

Table of Contents

Table of Contents

• About GlobalData

Table of Contents

• Executive Summary
• Players
• Trends
• Industry size and structure
• Definition of the dose CMO universe
• Industry demographics
• Global vs regional reach
• Dosage forms
• Major developments affecting industry structure
• Dose facility acquisitions
• Dose company acquisitions
• PE acquisitions
• Industry size and growth
• Dose manufacturing
• Inflation
• Components of growth
• Revenue by dosage form
• CMO market shares
• Characteristics of the largest CMOs
• COVID-19 Products Sales Forecast
• Analyzing Recent Dose CMO Industry Performance
• COVID-19 Influence
• High Inflation Effect
• Service-Specific Growth
• Cell and gene therapy investment
• Sponsor-CMO relationships
• What it means
• Value Chain
• Companies

Appendix

• Methodology
• Methodology for market size and growth estimates
• CMO classifications
• Bibliography
• Primary research - key opinion leaders
• Further reading
• About the Authors
• Contact Us